Upload
phamdieu
View
223
Download
0
Embed Size (px)
Citation preview
Product InnovationJonathan Howard-BrandSupply Specialist, Innovation Unit
28 March 2017
© UNICEF/UNI197921/Schermbrucker
Need: in depth analysis of full context
4UNICEF Product Innovation – UNICEF for every child
Purpose is to communicate requirements for products which are currently not available
Less prescriptive than an RFP to allow for creativity and innovation flexibility. Not final procurement specifications
Useful tool to gain understanding of UNICEF and partners’ product needs and to gain internal buy-in for driving R&D
In 2016, 7 Target Product Profiles were published
Available online here: https://www.unicef.org/supply/index_91816.html
UNICEF Product Innovation – UNICEF for every child
Development: working non-exclusively with developers
Industry : • Dialogue with UNICEF on maturity of
technology• Ensure clinical and regulatory approvals
UNICEF
• Clarity on needs (e.g amendments to a TPP or industry consultations)
• Field trials in UNICEF context to prove value and inform scale
• Convene regulatory partners/advisory committees for feedback
Scale: incentivizing through volume guarantees and trials
UNICEF has a number of ways to incentivise (“pull”) developers to invest in R&D, regulatory and related to the product.
Concretely, UNICEF can do one of the following ranging from less to more committing:
• Indicate willingness to procure products meeting the TPP• Commit to carrying out field trials of selected products
meeting the TPP selected through competitive bidding• Commit to working with key actors and national agencies
(governments and implementing partners) to drive interest in uptake of products meeting the TPP
• Legally commit (through an Advanced Purchase Commitment or an Advanced Market Commitment) to procure a given amount of products
Convergence of Product Innovation and Influencing Markets
• Foster competition• Drive voloume• Strategic/transparent procurement
• Field Trials (FT)• Programmatic and technical guidance• Engagements with partners, such as WHO • Advocacy to end-users and implementing
partners
How we increase perceived value:
How we reduce cost
Marketpull
Sustainable Market
Tipping Point
*Supply Financing Mechanism
*
Field Developers/Suppliers
Supply Division
• Define & Communicate Field Needs
• Enable Product Development• Field Trial/Pilot• Implementation & Scale
• Communicate bottlenecks• Highlight Demand• Implementation/scale
• Product Development• Quality Assurance• Clinical Validation • Production
Our Value Add
Challenges
Need Development Scale
Working through the tradeoffs to create a TPP that matches the
field needs.
Designing a PULL that ensure the right R&D
gets pulled.
Ensuring impact actually happens.
Zika Virus (ZIKV) Diagnostic
Key Activities:• Creation of TPPs to communicate the desired performance of products.
First time WHO, PAHO and UNICEF launched joint TPPs. • Zika Partner- Industry Consultation at SD with over 50 people subject
experts to share UNICEF’s Zika response strategy, exchange knowledge in an open and transparent forum, and communicate the need to accelerate product development through increased awareness of stakeholders’ challenges and needs.
• Initial forecast developed based on WHO classification of ZIKV transmission, environmental suitability for vector-borne transmission, potential target cohorts and various uptake scenarios.
• Coordination with USAID engaged in pull-mechanism, i.e. funding R&D to reduce time-to-market for POC diagnostics
What’s Next: • Continuous monitoring of the R&D landscape and consultations with
industry. Additionally, bilateral consultations with key pipeline manufacturers.
• Tendering• With Zika and market uncertainties, ensuring we share risk with industry
and make a balance to create a tipping point that makes a push-pull incentive that creates the right products and a healthy market.
2005
Safe Injection Device DevelopmentJoint UNICEF, WHO, UNFPA Policy Issued Auto-Disable (AD) as a step-stage technology (added attribute to already established technology)
1999
AD @ start
RUP
SB
AD
RUP/SIP
UNICEF Expressed preference for early activation of the disabling mechanism (to reduce risk of reuse) leading to redefining technology and improve product design
AD
AD @ start
2009
Adequate Supply Available with preferred AD mechanism for full award - with multiple suppliers
2008
Introducing the RUP & RUP/SIP feature for reconstitution of freeze dried vaccines
RUP/SIP
RUP
2015
Introducing the RUP & RUP/SIP in therapeutic injections- participation in WHO expert group for new guideline recommendation
Needle-free devices
What we are going to do? – our next steps
1. RFI / market analysis – what are you doing?2. If market does not meet UNICEF’s needs
a. Development of TPP(s)b. Industry Consultation (face-to-face/
online) c. Online transparency
3. If/when market meets UNICEF’s needsa. Field Trials (if needed) b. Share results and recommendations
4. Subject to FT results two routes: a. Positive results:
i. Procurement b. Negative results:
i. Work with industry on improvements